Navigation Links
Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
Date:4/18/2017

SAN DIEGO, April 18, 2017 /PRNewswire/ -- Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor in patients with Tourette Syndrome (TS). TS is a neurodevelopmental disorder characterized by sudden, involuntary movements and/or sounds called tics. Additionally, Abide has established a collaboration with the Tourette Association of America (TAA) to gain a better understanding of the unmet needs in the Tourette community.

The ongoing Phase 1b study in adults is a crossover design using ABX-1431, an orally available small molecule that modulates the activity of the endocannabinoid neurotransmitter system. Based on clinical observations with exocannabinoids, there is reason to believe that modulating the endocannabinoid system will improve TS symptoms and certain comorbidities, such as Attention Deficit-Hyperactivity Disorder (ADHD). The ABX-1431 study will provide the opportunity to assess whether a highly specific endocannabinoid modulator tested under controlled conditions will recapitulate the beneficial effects on the movement disorder that were previously observed with exocannabinoids.

"We are excited to begin this trial in adults with Tourette Syndrome, and we hope to subsequently extend our studies to children, since Tourette Syndrome is largely considered to be a disease of childhood," said Alan Ezekowitz, MBChB, DPhil, CEO and President of Abide Therapeutics. "As we continue to explore the potential utility of ABX-1431 in Tourette Syndrome, we are grateful for the opportunity to partner with the TAA to further understand the challenges faced by those affected by the condition."

"We are very excited to be partnering with Abide Therapeutics to raise awareness for and better serve the unmet needs of the Tourette Syndrome community," said John Miller, TAA President and CEO. "With no existing cure for Tourette Syndrome, there is an urgent need for safe, minimally invasive, and effective treatment options. The TAA and Abide Therapeutics have a mutual interest in advancing medical knowledge for Tourette, and we look forward to working together in our shared mission of improving the quality of life of all individuals affected by Tourette Syndrome."

ABX-1431 has successfully completed dosing in a first-in-human, placebo-controlled, Phase 1a study. The drug was generally well tolerated and there were no serious adverse events. Preliminary data from a PET occupancy study indicate dose-dependent brain penetrance of orally-administered ABX-1431 using [18F]ABX-1488, an Abide proprietary, MGLL-specific PET ligand. Furthermore, an fMRI study aimed at assessing the patterns of neural activity in the brain associated with ABX-1431 administration is scheduled to start dosing in the first quarter of 2017.

"Our previous studies suggest that the endocannabinoid system is involved in the pathophysiology of Tourette Syndrome. We very much hope that this study of ABX-1431 in adults with Tourette Syndrome will substantially improve the available treatment options for these patients," said Kirsten Müller-Vahl, MD, Professor of Psychiatry at the Department of Psychiatry, Social Psychiatry and Psychotherapy at the Hannover Medical School (MHH), Germany. Dr. Müller-Vahl is the Principal Investigator for this study.

About the Endocannabinoid System

MGLL is an enzyme that catalyzes the breakdown of the endocannabinoid 2-arachidonoylglycerol (2-AG), an endogenous ligand of the cannabinoid receptors CB1 and CB2, which are the molecular targets of the psychoactive component of cannabis, delta-9 tetrahydrocannabinol (THC). MGLL is the major regulator of 2-AG levels available to signal through CB1 and CB2. CB1 is the primary cannabinoid receptor in the nervous system, and its activation accounts for most of the neurobehavioral effects of THC. CB2 is found primarily on immune cells and mediates the immunosuppressive effects of cannabinoids. Direct activation of cannabinoid receptors by medicinal cannabis preparations elicits therapeutically beneficial effects on pain, spasticity, sleep, appetite, and nausea. ABX-1431 is expected to produce similar beneficial therapeutic effects through amplification of endogenous cannabinoid signaling.

About Abide Therapeutics

Abide Therapeutics combines an innovative discovery platform and a library of proprietary small molecules to address biological pathways with therapeutics that enhance the body's normal physiological response to disease. The platform enables Abide to quickly and efficiently identify, modify and validate small molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide's initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.

Abide is located in San Diego, California. To learn more, visit www.abidetx.com

Media Contact: Forrest Hull, forrest@abidetx.com; or Amanda Sellers, asellers@spectrumscience.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abide-therapeutics-announces-dosing-of-first-patient-in-phase-1b-study-of-abx-1431-in-tourette-syndrome-and-collaboration-with-tourette-association-of-america-300440519.html


'/>"/>
SOURCE Abide Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Abide Therapeutics Appoints Richard N. Kender to Board of Directors
2. Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer
3. Abide Therapeutics Appoints Donald Hertzog as Vice President, Early Lead Identification
4. Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator
5. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
6. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
7. H1 Pipeline on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) for 2017 Market Therapeutics Growth and Assessment at ReportsnReports.com
8. Dermata Therapeutics, LLC and Villani, Inc. Announce a Global License Agreement for a Natural Sponge Product for Skin Diseases
9. KNOW Bio Respiratory Has New Name, Novoclem Therapeutics, New Antimicrobial Drug Candidate for Lung, Respiratory Infections
10. Research Reports Initiation on Biotech Stocks -- Epizyme, Sierra Oncology, Five Prime Therapeutics, and AveXis
11. Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... Ariz. (PRWEB) , ... July 31, 2020 , ... ... received FDA clearance for reprocessing the St. Jude Medical BRK Transseptal Needle and ... transseptal needles is a milestone in single-use device reprocessing, as no other company ...
(Date:7/31/2020)... (PRWEB) , ... July 31, 2020 , ... Member Care ... the nation’s largest urgent care clinic operators the licensing of their cloud based membership ... the Member Care Solutions client family. Our software is the perfect match for many ...
(Date:7/31/2020)... ... July 31, 2020 , ... A June 29 article ... to have been caused by tiny worms that inhabited the mouths of those afflicted. ... details of small creatures that are commonly found in water supplies. Marina Del Rey-based ...
Breaking Medicine Technology:
(Date:7/22/2020)... ... July 22, 2020 , ... Whatever we call them ... people may like a summer glow,” notes Angie Seelal, a Certified Registered Physician Assistant ... spots that show up years later and make us look older.” , In terms ...
(Date:7/22/2020)... ... July 22, 2020 , ... ... launch of its new Data Curation as a Service (DCaaS) solution for payers, ... focus on specific clinical data curation parameters and are custom tailored to provide ...
(Date:7/18/2020)... ... July 17, 2020 , ... Nader Sanai, M.D., director ... have come together for the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, ... to increasing public awareness of glioblastoma , the most common and aggressive form ...
(Date:7/10/2020)... ... July 10, 2020 , ... Inversion therapy is defined by ... the spine and relieve back pain.” Ergo, the theory is that if the body’s ... implementing traction for the spine using the head and upper body as the "weights" ...
(Date:7/10/2020)... ... ... Ziegler, a specialty investment bank, is pleased to announce the successful closing of ... (Beacon Hill). The Series 2020 Bank Bonds include a $9,800,000 long-term component with ... be retired with initial entrance fees from the Project (detailed below). , ...
Breaking Medicine News(10 mins):